HNHiroshi Nakagomi

Hiroshi Nakagomi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroshi Nakagomi has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Key issues in surveillance of secondary breast cancer

    by Tomomi Oka, Hiroshi Nakagomi, Ayako Kimura, Kazushige Furuya, Masayuki Inoue

    Purpose To enable early detection of secondary cancers, such as contralateral breast cancer (CBC) or ipsilateral breast tumor recurrence (IBTR) in patients who have undergone breast cancer (BC) surgery, we examined the diagnostic history and surveillance challenges of CBC and IBTR. Methods We analyzed the clinical data of 111 patients with CBC and 66 with IBTR, focusing on follow-up, screening, and patient awareness. We also examined the sensitivity of each diagnostic modality. Results The interval between primary and secondary cancer exceeded 10 years in 48% of CBC cases and 44% of IBTR cases. After 10 years, the proportion of patients diagnosed through follow-up decreased, whereas diagnoses through screening and awareness increased significantly. Among the three diagnostic groups, more advanced cancers were observed in the awareness group. When comparing diagnostic sensitivity, subjective symptoms were reported at similar rates for CBC (43.2%) and IBTR (48.5%). However, mammography (MMG) was significantly lower in IBTR (36.2%) than in CBC (70.8%) (p = 0.00), and ultrasound sonography (US) was lower in IBTR (84.8%) than in CBC (95.4%) (p = 0.02). Conclusions During postoperative surveillance, MMG sensitivity in the preserved breast was limited, thus suggesting the essence of careful US examination. More advanced cancer in the awareness group suggested long-term surveillance beyond 10 years is crucial, with a focus on promoting breast awareness and appropriate screening program for individual patient after hospital follow-up.

  • Open Access

    Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer

    by Rui Kitadai, Shu Yazaki, Aya Kuchiba, Takashi Yamanaka, Sho Shiino, Chisako Yamauchi, Kenichi Harano, Motonobu Saito, Yosuke Hirotsu, Hisaki Aiba, et al.

    Despite the importance of genetic testing for risk assessment and treatment in breast cancer, the prognostic impact of germline pathogenic variants (PVs), especially in Asian populations, is unclear. We assessed the impact of germline PVs in patients with early‐stage breast cancer. This study included 7278 Japanese multihospital registry patients. PVs of ATM, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, and TP53 were evaluated. PV and non‐PV carriers were matched by age, histology, and stage. Associations between PVs and survival were assessed. The primary outcome was invasive disease‐free survival (IDFS). Secondary outcomes included relapse‐free survival (RFS), overall survival, and breast cancer‐specific survival. We identified 320 (4.4%) patients with BRCA1/2 PVs and 79 (1.1%) with PVs other than BRCA1/2 (non‐BRCA1/2). A total of 360 patients (BRCA1/2, n = 289; non‐BRCA1/2, n = 71) were matched to 720 noncarriers. Patients with BRCA1/2 PVs had significantly shorter 10‐year IDFS (adjusted hazard ratio (aHR) = 2.15; 95% confidence interval (CI), 1.61–2.86; p < 0.001); and RFS (aHR = 1.74; 95% CI, 1.25–2.44; p = 0.001) than noncarriers. Among patients with hormone receptor‐positive HER2‐negative breast cancer, BRCA1/2 PV carriers exhibited significantly shorter 10‐year IDFS than noncarriers, even those with stage I/II disease (total, aHR = 2.23; 95% CI, 1.55–3.23; p < 0.001, Stage I/II, aHR = 2.22; 95% CI, 1.43–3.44; p < 0.001). There was no significant difference in 10‐year IDFS between the non‐BRCA1/2 PV carrier and noncarrier groups (aHR = 1.40; 95% CI, 0.67–2.93; p = 0.37). Asian patients with breast cancer carrying germline BRCA1/2 PV, even those with a low recurrence risk, have significantly shorter 10‐year IDFS than noncarriers.


  • Open Access

    Comprehension for Breast Awareness, Dense Breast, and Hereditary Breast and/or Ovarian Cancer (HBOC) in participants of Breast Cancer Screening

    by Hiroshi Nakagomi, Katsuhiro Teramoto, Haruka Nakada, Kei Matsuda, Ryoko Yoneyama, Chiemi Kawai, Yoshinari Miura, Chiemi Kunugi, Junji Hirose, Yoshioki Yoda

    Background: It is important to promote breast awareness (BA) as an alternative to breast self-examination in order to improve the prognosis of breast cancer patients. Methods: We investigated the level of comprehension for BA among participants of the organized (n=7959) and the opportunistic (n=11541) breast cancer screening. In addition, we investigated the level of comprehension for dense breast (DB) and hereditary breast and/or ovarian cancer (HBOC) as knowledge necessary for optimal breast cancer screening. Results: The overall percentages of comprehension of BA, DB and HBOC were 24, 32, and 24%, respectively. The level of comprehension of BA, DB, and HBOC was lower among participants aged 50 years. First-time participants were less likely to be aware of BA, DB, and HBOC than those who had screening for the second time or more. On the other hand, there was no difference in the level of comprehension of BA between organized and opportunistic screening, but the level of awareness of BD and HBOC was significantly higher in participants of opportunistic screening. Conclusions: The level of comprehension for BA, DB and HBOC is still low in 2023. Our results indicates that screening is an important opportunity to educate something about the breast health literacy. We intend to conduct this survey and educational campaign over time to determine if those comprehension improve.

  • Dynamic change of cancer genome profiling in metachronous bilateral breast cancer with BRCA pathogenic variant

    by Ayako Kimura, Hiroshi Nakagomi, Masayuki Inoue, Tomomi Oka, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochizuki, Toshio Oyama, Masao Omata

    A 61-year-old woman with BRCA2 pathogenic variant had been treated for 20 years and showed dynamic changes in the genomic profile of her metachronous bilateral breast cancer and metastases. She underwent right breast conservation surgery at age 42-Genome 1, lung metastasis and left axillary lymph node metastasis at age 51, partial excision under local anesthesia for left breast cancer at age 53-Genome 2, left axillary lymph node dissection was added 6 month later-Genome 3. Then, olaparib was administered, and subsequently, left mastectomy was performed for the recurrence of left breast cancer at age 59-Genome 4. Genomic profile of the tumor was analyzed at four points (Genome 1–3 were analyzed by in house breast cancer panel, and Genome 4 was analyzed by Foundation One CDx). Two interesting findings emerged from these analyses. First, the genomic profile revealed that the left axillary lymph node metastasis, considered histologically from right breast cancer, was a metastasis from the left breast cancer. The second finding is that as the disease progressed, mutation profile became more diverse. The profile of the left breast cancer removed after olaparib and other treatments showed reversion mutation of BRCA2 and was diagnosed as tumor mutation burden high. Subsequent response to pembrolizumab was favorable.


  • TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer

    by Hideki Watanabe, Hiroshi Nakagomi, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochizuki, Masayuki Inoue, Ayako Kimura, Masao Omata

    Purpose The prognosis of HER2-positive breast cancer has improved with the development of anti-HER2 therapies. In order to further improve the prognosis of HER2-positive breast cancer, it is essential to elucidate the cells that survive during the therapy (drug-tolerant persister DTP). Methods Of the 2022 breast cancer patients operated at our institution during 2004–2018, 240 (12%) had HER2-positive breast cancer. Neo-adjuvant chemotherapy including trastuzumab (Tr-NAC) was administered to 94 of them. Forty-six of them were complete remission (CR), and 48 were non-CR. After 6.9 ± 3.7 years of follow-up, all 46 CR cases showed no recurrence (Cohort A), and 48 non-CR cases were divided into 31 cases with no recurrence (Cohort B) and 17 cases with recurrence (Cohort C). In addition to clinical backgrounds, we compared genomic profiles for 27 patients (Cohort A; 15/48, B; 7/31, and C; 5/17) who consented to genomic analysis. Results Genomic abnormalities of TP53 and PIK3CA were frequently observed in biopsy samples pre Tr-NAC, but we found no differences between CR (Cohort A) and non-CR (Cohorts B + C). Then, we examined both of pre and post Tr-NAC samples of Cohort B (7) and C (5) to see the relationship between recurrence and genomic abnormalities. TP53 mutations were significantly more prevalent in Cohort C (5/5, 100%) than cohort B (3/7, 43%) in the surgical sample after treatment (p = 0.04). PyClone analysis of TP53 mutations showed that the cellular frequency of TP53 clones increased in 4 of 5 patients in Cohort C and none of B. On the other hand, we found no enhancement of PIK3CA mutant clones in Cohort C. Conclusions The DTP after Tr-NAC associated with subsequent relapse had TP53 mutations, suggesting that overcoming DTP with TP53 mutations is the most important clinical challenge. Trial registration Not applicable.


  • Cystic degeneration during neo-adjuvant chemotherapy predicts squamous metaplasia of triple negative breast cancer: report of two cases

    by Masayuki Inoue, Ayako Kimura, Tomomi Oka, Aya Yajima, Yudai Higuchi, Tatsuki Endo, Hideki Watanabe, Hiroshi Nakagomi, Toshio Oyama

    Neo-adjuvant chemotherapy (NAC) has become a standard treatment for advanced breast cancer because of the advantage of monitoring drug sensitivity and enabling breast-conserving therapy. The changes during NAC are also important to know the biological characteristics of the tumor. We experienced two cases with cystic degeneration and enhancement of the cyst wall during NAC for triple negative breast cancer (TNBC). They were diagnosed to have breast cancer with squamous metaplasia. In case 1, a 37-year-old woman with right breast cancer diagnosed as TNBC, T3N3M0, Stage 3b was treated with NAC. MRI showed a cystic degeneration with a diameter of 3.5 cm and enhancement of the cyst wall, and the other nodules were extinguished. The histopathological finding of the surgical specimen revealed solid tubular carcinoma with squamous metaplasia. In case 2, a 58-year-old woman with right breast cancer diagnosed as HER2 enriched subtype, T2N0M0 stage 2 was treated with NAC containing trastuzumab. The post-NAC MRI showed extinguishment of the mass in the right breast, but showed a cystic lesion with 24 mm in diameter and enhancement of its wall in the left breast. She underwent breast conserving surgery for bilateral breast cancer, and histopathological finding of the surgical specimen indicated complete remission of right breast cancer and squamous cell carcinoma developed in the left breast. These changes are impressive and remind us that there are metaplastic changes (especially for squamous metaplasia) with resistance to chemotherapy.


  • PIK3CA-AKT pathway predominantly acts in developing ipsilateral breast tumor recurrence long after breast-conserving surgery

    by Hiroshi Nakagomi, Masayuki Inoue, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochiduki, Masao Omata

    Purpose Ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy is seen after a long interval, but the clinical classification of Residual Tumor Recurrence (RR) or Double Primary (DP) needs to be validated. We used genome profiling to identify the genetic alterations associated with IBTR. Methods Among 1881 breast cancer patients treated with breast-conserving therapy between 1999 and 2018, IBTR occurred in 52 patients (2.8%). Of these 22 patients who consented for genomic analysis of Primary Breast Cancer (T1) and IBTR (T2) were studied. When the same gene mutations in T1 and T2 were identified, it was classified as genomic residual recurrence gRR, and when no shared mutations identified, it was classified as gDP. The differences between clinical and genomic classification were compared. Furthermore, the pathway of the genes which were responsible for recurrence was also examined. Results Of 13 clinically diagnosed RRs (cRRs), 11 were gRR and 2 were gDPs, while of 9 cDPs, 6 were gDP and 3 gRR, with a match rate of 17/22 (77%). We searched for genes involved in IBTR: PIK3CA-AKT pathway mutations were found in 12 of 14 gRRs (86%) in T1, and only 2 of 8 gDPs (25%) with significant difference (p = 0.004). When both of PBC and IBTR compared, PIK3CA-AKT pathway abnormalities were 24/28 (86%) in the gRR and 5/16 (31%) in the gDP (p < 0.001). Conclusions Genome profiling revealed that abnormalities in the PIK3CA-AKT pathway in long-term residential recurrences and are a crucial molecular group in the development of IBTR.


  • Benefit of home parenteral nutrition (HPN) and chemotherapy in patients with invasive lobular carcinoma developed peritoneal metastases

    by Masayuki Inoue, Ayako Kimura, Tomomi Oka, Aya Yajima, Yudai Higuchi, Tatsuki Endo, Hideki Watanabe, Hiroshi Nakagomi

    The benefit of home parenteral nutrition (HPN) for patients with malnutrition due to peritoneal metastasis depends on the type of cancer. During the period 1999–2020, we treated 460 patients with metastatic and stage 4 breast cancer, 23 of whom were invasive lobular carcinoma (ILC). Of the 23 patients with ILC, 13 (57%) developed peritoneal metastasis, and 11 died of progression of peritoneal metastasis. Among these 11 patients, 2 patients who underwent surgery due to bowel obstruction, had no improvement, and died 1–4 months after surgery. The prognosis of the other 7 patients under BSC alone was poor, survival time were ranging from 1 to 5 months. The remaining two patients who were able to continue outpatient chemotherapy under HPN were able to prolong their survival time by 18 months and 26 months, respectively. We need to recognize that HPN and chemotherapy may prolong survival time in patients with peritoneal metastasis of ILC, and determine the indication for HPN based on the non-peritoneal life-threatening metastasis, length of treatment, availability of support for HPN management and outpatient chemotherapy, and the patient's willingness to accept it.


  • Open Access

    PIK3CA-AKT Pathway Predominantly Acts in Developing Ipsilateral Breast Tumor Recurrence Long After Breast Conserving Surgery

    by Hiroshi Nakagomi, Masayuki Inoue, Yosuke Hirotsu, Kenji Amemiya, Hitoshi Mochiduki, Masao Omata

    Purpose: Ipsilateral Breast Tumor Recurrence (IBTR) after breast-conserving therapy is seen after a long interval, but the clinical classification of Residual Tumor Recurrence (RR) or Double Primary (DP) needs to be validated. We used genome profiling to identify the genetic alterations associated with IBTR. Methods: Among 1,881 breast cancer patients treated with breast-conserving therapy between 1999 and 2018, IBTR occurred in 52 patients (2.8%). Of these 22 patients who consented for genomic analysis of Primary Breast Cancer ( T1) and IBTR (T2) were studied. When the same gene mutations in T1 and T2 were identified, it was classified as genomic residual recurrence gRR, and when no shared mutations identified, it was classified as gDP. The differences between clinical and genomic classification were compared. Furthermore, the pathway of the genes which were responsible for recurrence was also examined. Results: Of 13 clinically diagnosed RRs (cRRs), 11 were gRR and 2 were gDPs, while of 9 cDPs, 6 were gDP and 3 gRR, with a match rate of 17/22 (77%). We searched for genes involved in IBTR: PIK3CA-AKT pathway mutations were found in 12 of 14 gRRs (86%) in T1, and only 2 of 8 gDPs (25%) with significant difference (p=0.004). When both of PBC and IBTR compared, PIK3CA-AKT pathway abnormalities were 24/28 (86%) in the gRR and 5/16 (31%) in the gDP (p<0.001).Conclusions: Genome profiling revealed that abnormalities in the PIK3CA-AKT pathway in long-term residential recurrences and are a crucial molecular group in the development of IBTR.Trial registration: not applicable

  • A long-term survival case with recurrent esophageal adenosquamous carcinoma

    by Koichi Matsuoka, Masao Hada, Hayato Ohmori, Aya Yajima, Tatsunori Nadaya, Hideki Watanabe, Hiroshi Nakagomi, Toshio Oyama

    We experienced an extremely rare case of recurrent esophageal adenosquamous carcinoma showing cutis, bone and adrenal gland metastases. Furthermore, the patient showed complete remission by chemotherapy and irradiation, with a long-term survival of over 8 years. A 46-year-old man with esophago-gastric junction cancer of clinical stage II was administered two cycles of neo-adjuvant chemotherapy with FP (5FU 800 mg/mm2 Cisplatin 80 mg/mm2 every 3 weeks), subsequently, underwent esophagectomy and mediastinal and celiac lymph node dissection. However, at 1 month after the surgery, he was admitted again due to a 1 cm cutaneous metastasis at the anterior chest wall and left side adrenal gland metastasis. Furthermore, magnetic resonance imaging showed bone metastasis at the second cervical vertebra. He was administered weekly docetaxel at 40 mg/body (3 times every 4 weeks) for 27 cycles. Irradiation therapy (liniac 36 Gy/16Fr) was performed for the vertebral metastasis. The cutaneous and adrenal metastases were diminished and complete remission persisted for over 8 years.